|Referral date||01 March 2009|
Cancer reform strategy Batch 4
|Closing date for invited submissions / evidence submission:||TBC|
|1st appraisal committee meeting:||TBC|
|Executive Lead:||Peter Littlejohns|
|Technical Lead:||Joao Vieria|
|6 August 2010||
Nilotinib for the first line treatment of chronic myeloid leukaemia was referred to NICE as a Single Technology Appraisal (STA).
NICE have recently undertaken a draft scope consultation exercise and held a scoping workshop for the proposed appraisal of dasatinib for the first line treatment of chronic myeloid leukaemia. As a result of this work, the Department of Health has now asked NICE to carry out a multiple technology appraisal of dasatinib, nilotinib and standard-dose imatinib within their licensed indications for the first-line treatment of chronic myeloid leukaemia (including part-review of TA70) as part of our 24th wave work programme.
Therefore nilotinib will not be appraised through the STA process.
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance